ICYMI, this week we had stories about adherence issues in acne treatment, shin guard dermatitis, atopic dermatitis in skin of color patients, clinical trial news from Arcutis Biotherapeutics, and more.
Click here to answer this week's poll.
This week's edition of the Mainstream Patient features stories about psoriasis in skin of color, the best facial cleansing brushes, a new acne-focused skin care line, Joe Jonas' experience with injectables, and more.
Joshua Zeichner, MD, and Mona Gohara, MD, discuss how adherence becomes an issue in the treatment of acne and what factors lead to lack of adherence in patients.
Joshua Zeichner, MD, and Mona Gohara, MD, discuss the importance of the skin barrier and its importance in acne treatment.
Emergency Use Authorization provides a 2-dose primary series given 3 weeks apart.
Sarah Higgins, DNP, APRN, WHNP-BC, discusses the best career advice she ever got, what she believes is the biggest myth in the aesthetic industry, and what changes she would like to see take place in the field of aesthetic dermatology.
Peter Lio, MD, clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses how atopic dermatitis presents differently in pediatric patients, and the 2021 allergen of the year, acetophenone azine associated with shin guard dermatitis.
Domestic production to begin at Michigan-based pharmaceutical maker.
Three dermatologists discuss the case of an 18-year-old patient with AD who is exploring nonsteroidal options to manage his disease.
Drs Angela Lamb, Omar Noor, and Neal Bhatia share what they consider to be the biggest gaps in care for patients with SOC: patient/provider education, building trust, and appropriate diagnosis of AD.
In this week’s Pointers with Dr Portela, the 208SkinDoc gives his skin discoloration treatment tips.
Frank discussions about managing the disorder can boost patients’ self-esteem and quality of life.
Hiring investigators of color, educating and building trust with potential participants, and addressing funding can make clinical trials more diverse.
INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.
HHS agency warns “vishing,” combining scam emails and phone calls, is on the rise.